Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

Peking University First Hospital200 enrolled

Overview

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Alzheimer's Disease (AD)

Interventions

Multimodal Ophthalmic Imaging and plasma biomarkerDIAGNOSTIC_TEST

Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female participants aged ≥ 50 years; * Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN); * Signed informed consent form Exclusion Criteria: * Presence of other neurological disorders and systemic diseases that may cause cognitive impairment; * Inability to cooperate with cognitive assessments; * Refusal to undergo blood sampling.

Locations (1)

Peking University First Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

Differences in Multimodal Ophthalmic Imaging parameter values among groups

Time frame: Baseline

Secondary Outcomes

Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.